[1]张东霞.米非司酮在子宫内膜异位症患者腹腔镜手术中的应用研究[J].医学信息,2021,34(16):175-177.[doi:10.3969/j.issn.1006-1959.2021.16.050]
　ZHANG Dong-xia.Application of Mifepristone in Laparoscopic Surgery in Patients with Endometriosis[J].Medical Information,2021,34(16):175-177.[doi:10.3969/j.issn.1006-1959.2021.16.050]
点击复制

米非司酮在子宫内膜异位症患者腹腔镜手术中的应用研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年16期
页码:
175-177
栏目:
药物与临床
出版日期:
2021-08-15

文章信息/Info

Title:
Application of Mifepristone in Laparoscopic Surgery in Patients with Endometriosis
文章编号:
1006-1959（2021）16-0175-03
作者:
张东霞
（佳木斯市中心医院妇科，黑龙江 佳木斯 154002）
Author(s):
ZHANG Dong-xia
(Department of Gynecology,The Central Hospital of Jiamusi City,Jiamusi 154002,Heilongjiang,China)
关键词:
子宫内膜异位症; 促黄体激素释放激素类似物; 米非司酮; 腹腔镜手术; 性激素
Keywords:
Endometriosis; Luteinizing hormone releasing hormone analog; Mifepristone; Laparoscopic surgery; Sex hormones
分类号:
R711.71；R713
DOI:
10.3969/j.issn.1006-1959.2021.16.050
文献标志码:
A
摘要:
目的 观察促黄体激素释放激素类似物与米非司酮联合治疗，子宫内膜异位症腹腔镜手术患者的血清性激素水平的变化情况。方法 选取我院2019年5月~2020年10月收治的116例子宫内膜异位症患者，根据住院尾号奇、偶数分为两组，各58例，对照组给予促性腺激素释放激素治疗，观察组促性腺激素释放激素联合米非司酮，比较治疗前、结束时血清相关指标[促卵泡激素（FSH）、雌二醇（E2）、睾酮（T）、黄体生成素（LH）、血管内皮生长因子（VEGF）水平，基质金属蛋白酶-9（MMP-9）、脂氧素A4（LXA4）]及不良反应。结果 治疗结束时，观察组FSH、LH、E2、T低于对照组，差异有统计学意义（P＜0.05）；观察组VEGF、MMP-9水平低于对照组，LXA4高于对照组，差异有统计学意义（P＜0.05）；两组患者治疗期间失眠、潮热、阴道干涩等不良反应总发生率对比，差异无统计学意义（P＞0.05）。结论 子宫内膜异位症患者腹腔镜术后给予促黄体激素释放激素类似物联合米非司酮治疗，可改善机体血清性激素水平，缓解炎症状态，利于子宫内膜异位症腹腔镜手术患者恢复。
Abstract:
Objective To observe the changes of serum sex hormone levels in patients undergoing laparoscopic surgery for endometriosis during combined treatment of luteinizing hormone releasing hormone analogues and mifepristone.Methods A total of 116 patients with endometriosis admitted to our hospital from May 2019 to October 2020 were selected and divided into two groups according to the odd and even numbers of hospitalized tail numbers, with 58 cases in each group.The control group was given gonadotropin-releasing hormone therapy, and the observation group was given gonadotropin-releasing hormone combined with mifepristone.Compare serum related indicators before and at the end of treatment [Follicle Stimulating Hormone (FSH), Estradiol (E2), Testosterone (T), Luteinizing Hormone (LH), Vascular Endothelial Growth Factor (VEGF) Levels, Matrix Metalloproteinase-9 (MMP-9), lipoxin A4(LXA4)] and adverse reactions.Results At the end of the treatment, the FSH, LH, E2 and T of the observation group were lower than those of the control group,the difference was statistically significant (P＜0.05);The levels of VEGF and MMP-9 in the observation group were lower than those in the control group, and LXA4 was higher than the control group, the difference was statistically significant (P＜0.05);There was no statistically significant difference in the total incidence of adverse reactions such as insomnia, hot flashes, and vaginal dryness between the two groups of patients during treatment (P＞0.05).Conclusion The treatment of luteinizing hormone releasing hormone analogue combined with mifepristone in patients with endometriosis after laparoscopic surgery can improve the body’s serum sex hormone levels, relieve inflammation, and benefit the recovery of endometriosis patients undergoing laparoscopic surgery.

参考文献/References:

[1]魏海玲,张虹,黄斌斌,等.子宫内膜异位症患者腹腔镜术后联用米非司酮治疗的价值分析[J].中国妇产科临床杂志,2020,21(3):293-294. [2]Karwacka A,Zamkowska D,Radwan M,et al.Exposure to modern,widespread environmental endocrine disrupting chemicals and their effect on the reproductive potential of women:an overview of current epidemiological evidence[J].Hum Fertil,2017,22(1):2-25. [3]淡堰璇,张震宇.常规腹腔镜与迷你腹腔镜手术治疗子宫内膜异位症的比较[J].中国微创外科杂志,2018,18(4):31-33,40. [4]邵婕.米非司酮联合GnRH-a对子宫内膜异位症患者血清IGF-1、HMGB1水平的影响[J].中国妇幼保健,2019,34(7):1485-1487. [5]南燕,侯妍妍,李玉洁.不同剂量米非司酮对子宫内膜异位症大鼠异位内膜组织中环氧合酶-2和血管内皮生长因子表达的影响[J].新乡医学院学报,2019,36(6):26-29. [6]中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊治指南[J].中华妇产科杂志,2015,50(3):161-169. [7]朱丽波,丁少杰,竺天虹,等.子宫内膜异位症患者异位内膜和在位内膜组织中P2X3的表达及其意义[J].中华妇产科杂志,2017,52(4):264-267. [8]Hou XI,Zhou WM,Wang XK,et al.Fractalkine/CX3CR1 is involved in the pathogenesis of endometriosis by regulating endometrial stromal cell proliferation and invasion[J].Am J Reprod Immunol,2016,76(4):318-325. [9]Delbandi AA,Mahmoudi M,Shervin A,et al.1,25-Dihydroxy Vitamin D3 Modulates Endometriosis-Related Features of Human Endometriotic Stromal Cells[J].Am J Reprod Immunol,2016, 5(4):461-473. [10]Wang F,Wang AY,Chesnelong C,et al.ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways[J].Oncogene,2018,37(3):286-301. [11]Ben SA,Megdich F,Kacem O,et al.Vascular endothelial growth factor (VEGFA) gene variation in polycystic ovary syndrome in a Tunisian women population[J].BMC Genomics,2016,17(9 Supplement):748. [12]陈凤英,黄仕颖,何春容,等.多囊卵巢综合征患者血清血管内皮生长因子、内皮抑素水平及对卵巢间质血流的影响研究[J].中国综合临床,2018,34(2):170-172. [13]徐秀娟,杨玮.基质金属蛋白酶-2、基质金属蛋白酶-9和血管内皮生长因子联合检测对子宫内膜异位症的诊断价值[J].中国卫生检验杂志,2018,28(6):700-701. [14]王莉,黄冬梅,孙欣欣,等.GnRH-α辅助腹腔镜对中重度子宫内膜异位症患者5-脂氧化酶,脂氧素A4的影响[J].中国现代医学杂志,2018,28(21):103-107. [15]冯双苗,袁银花,张化莲.微小RNA-17-5p靶向调控S100钙结合蛋白A4对子宫内膜异位症在位子宫内膜间质细胞增殖和凋亡的影响[J].中华生物医学工程杂志,2019,25(2):183-188.

相似文献/References:

[1]郭晓钰.子宫内膜异位症性不孕的中西医治疗[J].医学信息,2022,35(09):58.[doi:10.3969/j.issn.1006-1959.2022.09.014]
　GUO Xiao-yu.Chinese and Western Medicine Treatment of Endometriosis Infertility[J].Medical Information,2022,35(16):58.[doi:10.3969/j.issn.1006-1959.2022.09.014]
[2]刘秀娟,马艳华,马月巧,等.腹腔镜联合罗氏内异方治疗中、重度子宫内膜异位症 相关不孕的疗效观察[J].医学信息,2018,31(13):77.[doi:10.3969/j.issn.1006-1959.2018.13.022]
　LIU Xiu-juan,MA Yan-hua,MA Yue-qiao,et al.Observation on the Curative Effect of Laparoscopic Combined with Luo’s Internal Prescription for Severe Endometriosis Related Infertility[J].Medical Information,2018,31(16):77.[doi:10.3969/j.issn.1006-1959.2018.13.022]
[3]刘秀娟,刘 辉.子宫内膜异位症相关性不孕的诊断及治疗研究[J].医学信息,2018,31(14):35.[doi:10.3969/j.issn.1006-1959.2018.14.012]
　LIU Xiu-juan,LIU Hui.Diagnosis and Treatment of Endometriosis Related Infertility[J].Medical Information,2018,31(16):35.[doi:10.3969/j.issn.1006-1959.2018.14.012]
[4]孔俊沣,钟 雯,刘 嵩,等.MRI对卵巢子宫内膜异位囊肿的诊断价值[J].医学信息,2022,35(11):165.[doi:10.3969/j.issn.1006-1959.2022.11.044]
　KONG Jun-feng,ZHONG Wen,LIU Song,et al.The Diagnostic Value of MRI in Ovarian Endometriotic Cyst[J].Medical Information,2022,35(16):165.[doi:10.3969/j.issn.1006-1959.2022.11.044]
[5]李跃飞,郑晶晶,于聪祥.干细胞标记物Musashi-1与子宫内膜异位症关系的研究进展[J].医学信息,2018,31(23):48.[doi:10.3969/j.issn.1006-1959.2018.23.014]
　LI Yue-fei,ZHENG Jing-jing,YU Cong-xiang.Advances in Research on the Relationship between Cell Marker Musashi-1 and Endometriosis[J].Medical Information,2018,31(16):48.[doi:10.3969/j.issn.1006-1959.2018.23.014]
[6]邬素珍,许焕英,陈 玉,等.子宫内膜异位症痛经患者体质分布规律研究[J].医学信息,2019,32(15):80.[doi:10.3969/j.issn.1006-1959.2019.15.025]
　WU Su-zhen,XU Huan-ying,CHEN Yu,et al.Study on the Distribution Law of Dysmenorrhea in Patients with Endometriosis[J].Medical Information,2019,32(16):80.[doi:10.3969/j.issn.1006-1959.2019.15.025]
[7]陈 玉,邬素珍,朱巧玲.子宫内膜异位症痛经患者情志状况的临床观察[J].医学信息,2020,33(01):106.[doi:10.3969/j.issn.1006-1959.2020.01.032]
　CHEN Yu,WU Su-zhen,ZHU Qiao-ling.Clinical Observation of Emotional Status in Patients with Endometriosis Dysmenorrhea[J].Medical Information,2020,33(16):106.[doi:10.3969/j.issn.1006-1959.2020.01.032]
[8]李国馨.妇科因素所致慢性盆腔痛的研究[J].医学信息,2020,33(05):59.[doi:10.3969/j.issn.1006-1959.2020.05.018]
　LI Guo-xin.Study on Chronic Pelvic Pain Caused by Gynecological Factors[J].Medical Information,2020,33(16):59.[doi:10.3969/j.issn.1006-1959.2020.05.018]
[9]杜 娟.亮丙瑞林治疗子宫内膜异位症伴不孕的应用[J].医学信息,2020,33(13):43.[doi:10.3969/j.issn.1006-1959.2020.13.012]
　DU Juan.Application of Leuprolide in the Treatment of Endometriosis with Infertility[J].Medical Information,2020,33(16):43.[doi:10.3969/j.issn.1006-1959.2020.13.012]
[10]李昌秀,黄 婷.直肠子宫内膜异位症1例报道[J].医学信息,2020,33(17):191.[doi:10.3969/j.issn.1006-1959.2020.17.060]

更新日期/Last Update: 1900-01-01